Edition:
United Kingdom

Sosei Group Corp (4565.T)

4565.T on Tokyo Stock Exchange

11,370JPY
22 Nov 2017
Change (% chg)

¥-110 (-0.96%)
Prev Close
¥11,480
Open
¥11,510
Day's High
¥11,520
Day's Low
¥11,170
Volume
518,200
Avg. Vol
447,275
52-wk High
¥15,140
52-wk Low
¥8,590

Chart for

About

Sosei Group Corporation is a holding company primarily engaged in the biopharmaceutical business. The Company is mainly involved in the research, development and sale of pharmaceutical drugs, including NVA237 and QVA149, used for chronic obstructive pulmonary disease; SO - 1105, used for oral thrush. As of March 31, 2013, the... (more)

Overall

Beta: 1.53
Market Cap(Mil.): ¥161,930.91
Shares Outstanding(Mil.): 16.97
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

BRIEF-Sosei Group to issue 2.1 mln new shares

* Says it plans to issue 2.1 million new shares through overseas offering

10 Nov 2017

BRIEF-Sosei Group to advance clinical development in Japan of HTL0018318 in patients with Dementia with Lewy Bodies (DLB)

* Says it gains a licence to develop and commercialise HTL0018318, a novel muscarinic M1 receptor agonist, in Japan as a potential new treatment for patients with dementia with Lewy bodies (DLB)

09 Nov 2017

BRIEF-Sosei Group unit says first subject dosed in Phase1 clinical study of novel selective muscarinic M4 agonist in development to treat major symptoms of Alzheimer's disease

* Says co's unit Heptares Therapeutics and Allergan announced that the first healthy subject has been dosed with the first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase 1 clinical study

01 Sep 2017

BRIEF-Sosei Group to sell Chiba-based pharmaceutical unit for $3.5 mln

* Says it will sell Chiba-based pharmaceutical unit to Formosa Pharmaceuticals, Inc., which is unit of Formosa Laboratories, Inc, for $3.5 million

04 Aug 2017

BRIEF- Sosei Group subsidiary Heptares enters strategic collaboration with PeptiDream

* Says its unit Heptares Therapeutics and PeptiDream Inc , a public Tokyo-based biopharmaceutical company, have entered into a strategic collaboration to discover, develop and commercialise novel therapeutics targeting an undisclosed G protein-coupled receptor (GPCR) with an important role in inflammatory diseases

29 Jun 2017

Earnings vs. Estimates